Recurrence of Hereditary Hemorrhagic Telangiectasia (HHT) After Liver Transplantation
Completed
- Conditions
- Hereditary Haemorrhagic TelangiectasiaLiver Transplant
- Interventions
- Other: Data collection from standard follow-up after liver transplant
- Registration Number
- NCT03942315
- Lead Sponsor
- Hospices Civils de Lyon
- Brief Summary
Liver transplantation (LT) has been proposed as a curative treatment in hereditary hemorrhagic telangiectasia (HHT) with severe hepatic involvement. The investigating team provides a long-term evaluation of graft status after LT for HHT with a focus on the risk of recurrence. The present study included all patients prospectively followed up after LT for HHT in the Lyon Liver Transplant Unit from 1993 to 2010 with a survival of more than 1 year.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 14
Inclusion Criteria
- Hereditary Hemorrhagic Telangiectasia (HHT) patient who underwent liver transplant for HHT
Read More
Exclusion Criteria
- Patient who died in the year following transplantation
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Liver transplant in Hereditary Hemorrhagic Telangiectasia Data collection from standard follow-up after liver transplant Hereditary Hemorrhagic Telangiectasia (HHT) patients who underwent a liver transplant in Lyon between 1993 and 2010, and who survived more than 1 year after transplantation.
- Primary Outcome Measures
Name Time Method Change in graft status after liver transplant for Hereditary Haemorrhagic Telangiectasia (HHT) (risk of recurrence) Every 6 months after transplantation up to 5 years Recurrent clinical examinations (including laboratory, histological and radiological investigations)
- Secondary Outcome Measures
Name Time Method